Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes

AIM: To investigate the association of different categories of baseline cardio‐metabolic risk factors on the treatment effects of empagliflozin 10 and 25 mg when added as second‐line therapy to metformin in patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Patients aged 18 years or older w...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes Obes Metab
Huvudupphovsmän: Inzucchi, Silvio E., Davies, Melanie J., Khunti, Kamlesh, Trivedi, Prabhav, George, Jyothis T., Zwiener, Isabella, Johansen, Odd Erik, Sattar, Naveed
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2020
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839733/
https://ncbi.nlm.nih.gov/pubmed/33084149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14234
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk